MYX — Mayne Pharma Cashflow Statement
0.000.00%
- AU$568.72m
- AU$481.22m
- AU$395.47m
- 68
- 59
- 62
- 67
Annual cashflow statement for Mayne Pharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | -30.4 | -22.2 | -32.3 | -38.9 | -2.65 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | 99.8 | 58.9 | -7.21 | -42.7 | -15.3 |
Capital Expenditures | -47.1 | -25.1 | -11.9 | -220 | -20.9 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -8.76 | -24.1 | -16.7 | 693 | 74.3 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -55.9 | -49.2 | -28.5 | 473 | 53.4 |
Financing Cash Flow Items | — | -11.6 | -9.41 | -4.81 | 5.75 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 4.52 | -40.4 | 27.6 | -432 | -19.9 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 48.8 | -39.8 | -1.31 | -4.06 | 17.5 |